3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
4
Phase 3
2
Phase 4
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
13
Breast Neoplasms
9
Prostatic Neoplasms
4
Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Pain, Postoperative
3
Ovarian Neoplasms
3
Neoplasm Metastasis
3
Fallopian Tube Neoplasms
3
Stomach Neoplasms
2
Pancreatic Neoplasms
2
Lymphoma
2
Hemorrhage
2
Carcinoma, Renal Cell
2
Carcinoma, Hepatocellular
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Thromboembolism
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Peritoneal Neoplasms
1
Peripheral Nervous System Diseases
1
Pancreatic Cyst
1
Pain
1
Non-Muscle Invasive Bladder Neoplasms
1
Neurotoxicity Syndromes
1
Myofibroma
1
Multiple Myeloma
1
Metabolic Diseases
1
Melanoma
1
Interventions
Oxaliplatin
56
Capecitabine
49
Fluorouracil
37
Cisplatin
37
S 1 (combination)
23
Paclitaxel
18
Docetaxel
18
Leucovorin
16
pembrolizumab
13
Irinotecan
12
apatinib
11
titanium silicide
9
XELOX
9
Trastuzumab
9
Nivolumab
9
Hyperthermic Intraperitoneal Chemotherapy
8
Epirubicin
8
Drug Therapy
8
Tegafur
7
Radiotherapy
6
Neoadjuvant Therapy
6
gimeracil
5
Surgical Procedures, Operative
5
Gastrectomy
5
Chemotherapy, Adjuvant
5
tislelizumab
4
S-1 plus cisplatin
4
Ramucirumab
4
zolbetuximab
3
sintilimab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Stomach Neoplasms
×
Saline Solution
×
Clear all
NCT03221426
2026-03-09
KEYNOTE-585
Merck Sharp & Dohme LLC
Phase 3
Completed
1,007 enrolled
25 charts
NCT04882241
2026-03-06
KEYNOTE-585
Merck Sharp & Dohme LLC
Phase 3
Completed
120 enrolled
17 charts